Evidence map›Paper›PMID 41027992›Full record

ArticleNature communications2025

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring.

Cassandra J Hatzipantelis, Min Liu, Adam Love, Sadie J Leventhal, Hero Maera, Srinidhi Viswanathan, Emily Avetisyan, Liana Belinsky, McKenna M Rangel, Nina J Jain and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Psychedelic therapy and postpartum depression: priorities and prospects.Therapeutic advances in psychopharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cassandra J HatzipantelisInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA.ORCID http://orcid.org/0000-0001-5376-7887
Min LiuInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA.ORCID http://orcid.org/0000-0002-4698-6667
Adam LoveDepartment of Psychology, University of California, Davis, Davis, CA, USA.
Sadie J LeventhalDepartment of Psychology, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0009-0000-2117-5852
Hero MaeraInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA.
Srinidhi ViswanathanDepartment of Psychology, University of California, Davis, Davis, CA, USA.
Emily AvetisyanDepartment of Psychology, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0009-0002-5713-8281
Liana BelinskyDepartment of Psychology, University of California, Davis, Davis, CA, USA.
McKenna M RangelDepartment of Psychology, University of California, Davis, Davis, CA, USA.
Nina J JainGlobal Disease Biology, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0009-0005-5347-8539
Max KellyGenetics and Genomics, University of California, Davis, Davis, CA, USA.
Claire CopelandDepartment of Psychology, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0009-0000-1741-1322
Yara A KhatibInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA.ORCID http://orcid.org/0000-0002-8342-7100
Oliver FiehnInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA.ORCID http://orcid.org/0000-0002-6261-8928
David E OlsonInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA. deolson@ucdavis.edu.ORCID http://orcid.org/0000-0002-4517-0543
Danielle S StolzenbergInstitute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, USA, CA. dstolzenberg@ucdavis.edu.ORCID http://orcid.org/0000-0002-1498-5299

Funding

Epigenetic Mechanisms Regulate the Development of Parental BehaviorR01HD087709 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI STOLZENBERG, DANIELLE SUZANNE · 2016 to 2020
$1.6M
Supplement: Chemical and Molecular Tools for Modulating GPCR FunctionR35GM148182 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI David E Olson · 2023 to 2026
$1.5M
NICHD NIH HHS R01 HD087709NIGMS NIH HHS R35 GM148182U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01HD087709U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM148182
6 · The paper itself

Abstract

Psilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders. However, the efficacy and safety of psilocybin in peripartum mood disorders has not been investigated. We used a social stress model to examine the effects of psilocybin in parous mice and their offspring. Social stress induced maternal withdrawal and increased stress-related behaviors - none of which were ameliorated by psilocybin. Weeks later, psilocybin-treated dams were more anxious, regardless of stress exposure. In contrast, psilocybin-treated virgin females were unaffected. Though reproductive status did not affect psilocybin pharmacokinetics, serotonin receptor transcription and 5-HT2A receptor-dependent responses were reduced in dams. Offspring exposed to maternal psilocybin during breastfeeding exhibited anhedonia in adulthood. Here, we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period.

Indexed as

HallucinogensPostpartum PeriodPsilocybinAnhedoniaAnimalsAnxietyBehavior, AnimalFemaleMaleMaternal BehaviorMiceMice, Inbred C57BLMothersPregnancyReceptor, Serotonin, 5-HT2AStress, PsychologicalHallucinogensPsilocybinReceptor, Serotonin, 5-HT2A

Identifiers

PMID41027992
PMCPMC12485072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.